Observational Study of Survival Outcomes of Stage IV Cancer Patients

April 27, 2013 updated by: Cure Cancer Worldwide Corporation

Observational Study of Survival Times of Stage IV Cancer Patients

Patients diagnosed with Stage IV cancer (solid tumors only) are evaluated to determine whether they are candidates for traditional chemotherapy. If eligible, patients are offered traditional chemotherapy, low-dose chemotherapy, or palliative care. If ineligible, patients are offered low-dose chemotherapy or palliative care. Patients will be monitored for 5 years and survival data recorded.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shaanxi
      • Yang Ling, Shaanxi, China
        • Yang Ling Demonstration Zone Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

primary care clinic

Description

Inclusion Criteria:

  • Presenting with Stage IV cancer (solid tumors only)

Exclusion Criteria:

  • Patient declines inclusion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Cohorts and Interventions

Group / Cohort
1. Eligible RCT/Elect RCT
Eligible for regular chemotherapy, elects and receives regular chemotherapy
2. Eligible RCT/Elect LDC
Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
3. Eligible RCT/Elect PCO
Eligible for regular chemotherapy, elects and receives palliative care only
4. Ineligible RCT/Elect LDC
Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
5. Ineligible RCT/Elect PCO
Ineligible for regular chemotherapy, elects and receives palliative care only

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
survival
Time Frame: months 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60
months 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cure Cancer Worldwide Corporation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

April 27, 2013

First Submitted That Met QC Criteria

April 27, 2013

First Posted (Estimate)

May 1, 2013

Study Record Updates

Last Update Posted (Estimate)

May 1, 2013

Last Update Submitted That Met QC Criteria

April 27, 2013

Last Verified

April 1, 2013

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • YLDZH-OS-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Survival

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe